Upregulated insulin secretion in insulin-resistant mice: evidence of increased islet GLP1 receptor levels and GPR119-activated GLP1 secretion
Authors:
- L AhlkvistLAL Ahlkvist
- B AhrénBAB Ahrén
Open Access
- 1 June 2013
- journal article
- research article
- Published by Bioscientifica in Endocrine Connections
- Vol. 2 (2) , 69-78
Abstract
We previously demonstrated that the overall incretin effect and the β-cell responsiveness to glucagon-like peptide-1 (GLP1) are increased in insulin-resistant mice and may contribute to the upregulated β-cell function. Now we examined whether this could, first, be explained by increased islet GLP1 receptor (GLP1R) protein levels and, secondly, be leveraged by G-protein-coupled receptor 119 (GPR119) activation, which stimulates GLP1 secretion. Female C57BL/6J mice, fed a control (CD, 10% fat) or high-fat (HFD, 60% fat) diet for 8 weeks, were anesthetized and orally given a GPR119 receptor agonist (GSK706A; 10 mg/kg) or vehicle, followed after 10 min with gavage with a liquid mixed meal (0.285 kcal). Blood was sampled for determination of glucose, insulin, intact GLP1, and glucagon, and islets were isolated for studies on insulin and glucagon secretion and GLP1R protein levels. In HFD vs CD mice, GPR119 activation augmented the meal-induced increase in the release of both GLP1 (AUCGLP1 81±9.6 vs 37±6.9 pM×min, P=0.002) and insulin (AUCINS 253±29 vs 112±19 nM×min, PPP=0.014) but not in control mice. Islet GLP1R protein levels was higher in HFD vs CD mice (0.8±0.1 vs 0.5±0.1, P=0.035). In conclusion, insulin-resistant mice display increased islet GLP1R protein levels and augmented meal-induced GLP1 and insulin responses to GPR119 activation, which results in increased glucose elimination. We suggest that the increased islet GLP1R protein levels together with the increased GLP1 release may contribute to the upregulated β-cell function in insulin resistance.Keywords
This publication has 45 references indexed in Scilit:
- Glycaemic efficacy of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors as add‐on therapy to metformin in subjects with type 2 diabetes—a review and meta analysisDiabetes, Obesity and Metabolism, 2012
- Glucose-Dependent Insulinotropic PolypeptideDiabetes, 2011
- Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 DiabetesDiabetes Care, 2011
- GPR119 Is Essential for Oleoylethanolamide-Induced Glucagon-Like Peptide-1 Secretion From the Intestinal Enteroendocrine L-CellDiabetes, 2009
- Discovery of the First Potent and Orally Efficacious Agonist of the Orphan G-Protein Coupled Receptor 119Journal of Medicinal Chemistry, 2008
- Expression of the GLP-1 Receptor in Mouse, Rat, and Human PancreasJournal of Histochemistry & Cytochemistry, 2008
- GPR119, a novel G protein‐coupled receptor target for the treatment of type 2 diabetes and obesityBritish Journal of Pharmacology, 2008
- The augmenting effect on insulin secretion by oral versus intravenous glucose is exaggerated by high-fat diet in miceJournal of Endocrinology, 2008
- Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptorBiochemical and Biophysical Research Communications, 2005
- Islet adaptation to insulin resistance: mechanisms and implications for interventionDiabetes, Obesity and Metabolism, 2004